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Background. Human immunodeﬁciency virus (HIV) coinfection accelerates liver disease progression in individ-
uals with chronic hepatitis C. We evaluated the associations of CD4, HIV RNA, and antiretroviral therapy (ART)-
induced CD4 recovery with liver diagnoses in a prospective cohort of injecting drug users (IDUs).
Methods. We evaluated 383 coinfected IDUs in the Boston area, prospectively observed for amedian of 1.8 years. Liver
disease progression included the ﬁrst occurrence of hepatocellular carcinoma, variceal bleeding, ascites, encephalopathy,
or death due to hepatic failure. Multivariable-adjusted extended Cox models were speciﬁed to estimate hazard ratios
(HRs) for comparisons of CD4, change in CD4 (from nadir), andHIVRNAwith respect to liver disease progression events.
Results. Twenty-four persons experienced a liver disease progression event over 1155 person-years (2.1 per 100 person-
years), including 20 deaths attributed to end-stage liver disease (1.7 per 100 person-years). CD4 at baseline and over follow-
up strongly predicted liver disease progression (baseline CD4 <200 vs ≥200: HR = 5.23, 95% conﬁdence interval [CI],
2.30–11.92; time-updated CD4 <200 vs ≥200: HR = 11.79, 95% CI, 4.47–31.07). Nadir CD4 was also a strong indicator
(<100 vs≥100: HR = 3.52, 95%CI, 1.54–8.06). A lack of CD4 recovery (failure to increase 100 cells over nadir) among ART
initiators was associated with increased risk (HR= 7.69; 95% CI, 2.60–22.69). Human immunodeﬁciency virus RNA was
not signiﬁcantly associated with liver disease progression.
Conclusions. Impaired immune function was highly predictive of liver disease progression in this cohort of IDUs, and
a lack of CD4 recovery on ART was associated with increased risk of progression to HCV-associated liver disease.
Keywords. CD4; CD4 lymphocyte count; drug users; hepatitis C; highly active antiretroviral therapy; HIV; im-
mune reconstitution; liver/hepatitis; viral load.
Liver complications have emerged as a leading nonac-
quired immune deﬁciency syndrome-related cause of mor-
bidity and mortality among human immunodeﬁciency
virus (HIV)-infected populations receiving combination
antiretroviral therapy (ART) [1–3]. Human immunode-
ﬁciency virus coinfection in the context of chronic hep-
atitis C virus (HCV) infection accelerates progression
to clinical liver outcomes, at least among hemophiliacs
[4–6], although the mechanisms have yet to be fully char-
acterized. This is a signiﬁcant issue in the United States,
where 250 000–300 000 individuals (up to 30% of the
HIV-infected population) are coinfected [7, 8]. The
importance of this is magniﬁed in populations of HIV-
infected injecting drug users (IDUs), where the preva-
lence of HCV coinfection can reach 90% or more due
to a shared mode of transmission [9–11].
Recovery and/or maintenance of an adequate CD4
count could facilitate the necessary immune response
to control HCV and slow the progressive course of
Received 22 October 2014; accepted 14 January 2015.
Correspondence: C. Robert Horsburgh Jr, MD, Boston University School of Public
Health, Department of Epidemiology, 715 Albany Street, Boston, MA 02118
(rhorsbu@bu.edu).
Open Forum Infectious Diseases
© The Author 2015. Published by Oxford University Press on behalf of the Infectious
DiseasesSocietyofAmerica. This is anOpenAccessarticle distributedunder the terms
of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://
creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial
reproduction and distribution of the work, in any medium, provided the original work
is not altered or transformed in any way, and that the work is properly cited. For
commercial re-use, please contact journals.permissions@oup.com.
DOI: 10.1093/oﬁd/ofv019
CD4 and HCV Liver Events in HIV-Coinfected IDU • OFID • 1
hepatic ﬁbrosis. Some prior studies have suggested that CD4
count may be inversely associated with ﬁbrosis, cirrhosis, hepat-
ic decompensation, and/or death due to end-stage liver disease
[12–19], although others have not [20–23]. There appears to be
a complex interplay between the 2 viruses, host immunologic
response, and treatment. Antiretroviral therapy has been
shown to improve control of HIV and HCV [24–26], but the
extent to which this effect is mediated by CD4 count and/or
HIV viral load (VL) changes is unclear. In addition, previous
studies have suggested that HIV- and HCV-coinfected individ-
uals may have lesser recovery of CD4 count after being treated
with ART compared with HIV-monoinfected persons [27–33].
Within coinfected populations, a greater CD4 rebound after
ART could be an important protective factor with respect to
liver outcomes.
Human immunodeﬁciency virus itself has been postulated to
exacerbate chronic HCV by directly infecting hepatocytes or in-
teracting with other cell types that affect liver function [34].
It follows then that HIV VL could affect progression of liver dis-
ease among coinfected populations to some degree [35, 36].
The goal of this prospective study was to estimate the predic-
tive values of CD4, HIV VL, and ART-induced CD4 recovery
with respect to clinical progression events related to chronic
HCV liver disease in an urban cohort of HIV/HCV-coinfected
IDUs.
METHODS
Study Population and Assessments
The study population was drawn from the Hepatitis C, HIV and
Related Morbidity (CHARM) cohort study conducted at Boston
University Medical Center and its afﬁliated healthcare centers.
The CHARM study was initiated in August 2000 to prospective-
ly evaluate the natural history of HCV infection and HIV/HCV
coinfection in an inner city IDU population. Details on the
CHARM cohort have been published elsewhere [37, 38]. Inject-
ing drug users who were 18 years or older and had serologic ev-
idence of HCV infection were eligible for the CHARM study. Of
444 HIV/HCV-coinfected individuals in CHARM, 10 enrolled
after October 2007 (2%), 50 did not have available CD4 mea-
sures at baseline and for at least 1 follow-up visit (11%), and
1 was found to have had a liver disease progression event before
enrollment (<1%). Thus, 383 (86%) IDUs met the inclusion cri-
teria for this particular analysis. The CHARM study and the
current analyses have been approved by the Boston University
and Harvard University Institutional Review Boards, and in-
formed consent was obtained from all participants.
Study visits and medical chart reviews for the CHARM co-
hort were conducted at enrollment and annually thereafter; as
of 2005, follow-up visits and chart reviews were conducted
semiannually. Patients were generally seen in the participating
clinics as per usual HIV care at approximate 3-month intervals,
at which time laboratory values, including CD4+ T-cell counts
and HIV plasma RNAVL, were collected. In addition, informa-
tion on demographics, diagnoses, laboratory assays, substance
use, and medication history was assessed by questionnaire
and conﬁrmed by chart review.
Liver Disease Progression Outcome
The primary outcome of interest, clinical liver disease progres-
sion, was deﬁned as the ﬁrst diagnosis of any of the following
events: HCV-associated encephalopathy, variceal bleeding, asci-
tes, spontaneous bacterial peritonitis, hepatocellular carcinoma,
or death due to end-stage hepatic failure. Information on liver
events was obtained from patients during study interviews, sup-
plemented by chart review, and adjudicated and conﬁrmed by a
panel of clinical experts. Deaths were initially identiﬁed by chart
review and conﬁrmed via annual review of Massachusetts Death
Registries and National Death Index searches.
Statistical Methods
Participants were considered to be at risk from study enrollment
until the ﬁrst occurrence of a liver disease progression event,
death from any cause, loss to follow-up, or December 31,
2007. Longitudinal data were divided into 3-month intervals
for the purposes of analysis. CD4 count (and change in CD4
from nadir), HIV RNA VL, ART initiation status, outcomes,
and follow-up status were updated at each time point. If a
value for CD4 or VL was missing for a given interval, previous
values were carried forward for up to 1 year. Study participants
who were lost to follow-up (did not return for a visit during the
study period and had no data available for over 1 year) were
censored at the time of their last known visit. Cox regression
models were extended to include time-dependent variables
and used to calculate unadjusted and multivariable-adjusted
hazard ratios (HRs) and 95% conﬁdence intervals (CIs). Ad-
justed models considered the covariates shown in Table 1. Re-
duced models were ﬁt by removing covariates not associated
with the outcome and which did not change the CD4 or VL ef-
fect estimate by 10% or more. All models were ﬁt using SAS ver-
sion 9.2 (SAS Institute Inc., Cary, NC).
RESULTS
Clinical liver disease progression events occurred in 24 of 383
study participants over 1155 person-years of follow-up (median
1.8, maximum 7.5 person-years). Of the 24 incident events, 12
(50%) were deaths due to end-stage liver disease; 10 (42%) were
1 or more diagnoses representative of hepatic decompensation
(ascites, hepatic encephalopathy, spontaneous bacterial perito-
nitis, variceal bleeding); and 2 (8%) were hepatocellular carcino-
mas. Eighty-one individuals (21%) were lost to follow-up after
contributing a median of 2.0 person-years. Distributions of de-
mographic and clinical characteristics by CD4 count and HIV
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VL status at baseline are displayed in Table 1. Age at enrollment
ranged from 24 to 69 years (median 45), and there was a higher
proportion of older patients among the high CD4 and HIV
RNA <75 copies/mL categories. Nearly three-quarters were
male, and black non-Hispanics (45%) were represented more
than other ethnicities. Most were not diabetic, but 272 had
markers of hepatitis B virus (HBV) infection: of these, 9 had ev-
idence of active infection (positive DNA, surface antigen, or e
antigen), whereas 263 had evidence of prior infection only (sur-
face or core antibody). Where known, patients were largely
Table 1. Distribution of Baseline Characteristics Overall and in Relation to CD4 Count (Cells/µL) and HIV Viral Load (Copies/mL)
Variablea
Total N = 383
N (%)b
CD4 Count (Cells/mm3) HIV RNA Viral Load (Copies/mL)
<200 N= 89
N (%)b
≥200 N = 288
N (%)b
≤75 N = 155
N (%)b
76–10 000
N= 119 N (%)b
>10 000 N = 92
N (%)b
Age >45 years 212 (55) 43 (48) 166 (58) 107 (69) 62 (52) 34 (37)
Male 276 (72) 66 (74) 205 (71) 118 (76) 78 (66) 66 (72)
Race
Black non-Hispanic 171 (45) 36 (40) 132 (46) 76 (49) 48 (40) 38 (41)
White non-Hispanic 104 (27) 24 (27) 78 (27) 38 (25) 38 (32) 25 (27)
Hispanic 100 (26) 28 (31) 71 (25) 37 (24) 32 (27) 26 (28)
Other 8 (2) 1 (1) 7 (2) 4 (3) 1 (1) 3 (3)
History of diabetes 41 (11) 9 (10) 31 (11) 24 (15) 8 (7) 7 (8)
Markers of HBV 272 (78) 68 (83) 200 (76) 111 (77) 81 (76) 71 (80)
FIB-4
<1.45 (mild fibrosis) 151 (41) 32 (38) 115 (41) 64 (42) 46 (39) 36 (40)
1.45–3.25 (moderate) 147 (40) 29 (34) 117 (42) 61 (40) 48 (41) 34 (38)
>3.25 (advanced) 72 (19) 24 (28) 48 (17) 29 (19) 24 (20) 19 (21)
HCV genotype 1 176 (80) 41 (85) 133 (79) 74 (77) 59 (83) 39 (80)
HCV viral load ≥106 IU/mL 106 (47) 31 (58) 74 (44) 39 (44) 36 (51) 28 (47)
HCV treatment 27 (7) 4 (5) 23 (8) 13 (9) 9 (8) 5 (6)
Duration of IDU >25 years 154 (48) 40 (51) 113 (47) 67 (51) 52 (53) 30 (38)
Current IDU 103 (27) 30 (34) 71 (25) 30 (20) 36 (31) 30 (33)
AUDIT
<8 102 (56) 24 (51) 76 (58) 40 (63) 34 (57) 24 (46)
8–19 (hazardous) 54 (30) 14 (30) 37 (28) 13 (21) 18 (30) 20 (38)
≥20 (dependence) 27 (15) 9 (19) 18 (14) 10 (16) 8 (13) 8 (15)
Nadir CD4
<50 61 (16) 46 (52) 15 (5) 22 (14) 19 (16) 18 (20)
50–199 114 (30) 42 (48) 71 (25) 48 (31) 31 (26) 32 (35)
≥200 203 (54) 0 (0) 202 (70) 85 (55) 69 (58) 41 (45)
CD4
<200 89 (24) 89 (100) 0 (0) 19 (12) 26 (22) 40 (43)
200–499 161 (43) 0 (0) 161 (56) 72 (47) 54 (45) 32 (35)
≥500 127 (34) 0 (0) 127 (44) 63 (41) 39 (33) 20 (22)
HIV RNA
≤75 155 (42) 19 (22) 135 (48) 155 (100) 0 (0) 0 (0)
76–10 000 119 (33) 26 (31) 93 (33) 0 (0) 119 (100) 0 (0)
>10 000 92 (25) 40 (47) 52 (19) 0 (0) 0 (0) 92 (100)
Initiated ART
At baseline 281 (81) 65 (79) 212 (82) 130 (88) 83 (80) 62 (78)
In follow-up 37 (11) 12 (15) 25 (10) 13 (9) 10 (10) 9 (11)
Never 27 (8) 5 (6) 21 (8) 5 (3) 11 (11) 9 (11)
Abbreviations: ART, antiretroviral therapy; AUDIT, alcohol use disorders identification test; FIB-4, fibrosis-4; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human
immunodeficiency virus; IDU, injecting drug use.
a Missing observations for each variable (N, %): age, 0 (0); sex, 0 (0); race, 0 (0); diabetes, 0 (0); HBV, 33 (9); FIB-4, 13 (3); HCV genotype, 162 (42); HCV viral load, 157
(41); HCV treatment, 19 (5); years of IDU, 60 (16); current IDU, 3 (1); alcohol, 200 (52); nadir CD4, 5 (1); CD4, 6 (2); HIV viral load, 17 (4); ART initiation, 38 (10).
b Percentages are among the nonmissing.
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infected with HCV genotype 1, and HCV RNA was inversely
associated with CD4 count. Few (7%) reported having been
treated for HCV infection with interferon/ribavirin. Nineteen
percent were characterized at enrollment as having advanced
liver ﬁbrosis evidenced by ﬁbrosis-4 (FIB-4) above 3.25, a vali-
dated index score based on age and liver function biomarkers
[39]. Advanced ﬁbrosis as deﬁned by FIB-4 was elevated
among those with low baseline CD4 (28% vs 17%). Approxi-
mately half the population had been injecting drugs for more
than 25 years, and 27% reported that they were currently inject-
ing (within 6 months of enrollment). Forty-four percent report-
ed hazardous alcohol intake as deﬁned by an AUDIT score ≥8.
Most had initiated ART, and 42% had suppressed HIV VL at
enrollment.
Table 2 presents unadjusted HRs for liver disease progression
for covariates other than CD4 and VL. We observed no associ-
ation of any of these covariates with liver disease progression,
although HRs were slightly elevated for male vs female gender
(HR = 2.33; 95% CI, 0.80–6.84) and earlier year of enrollment
(≤2001 vs >2001: HR = 2.37; 95% CI, 0.87–6.46).
Table 3 summarizes the HRs for the associations of CD4
measures with liver disease progression. Overall, CD4 variables
were consistently strong and signiﬁcant predictors of liver out-
comes, with and without adjustment for covariates. In the ad-
justed model, those with a nadir <100 cells/μL had 3.5 times the
risk of liver disease progression relative to those with nadirs of
100 or more (adjusted HR [aHR] = 3.52; 95% CI, 1.54–8.06).
Baseline CD4 <200 cells/mm3 compared with >200 cells/mm3
was also associated with a signiﬁcantly increased risk (aHR =
5.23; 95% CI, 2.30–11.92). Covariate adjustment generally
increased the magnitude of the associations between CD4
and liver outcomes compared with unadjusted estimates
(Table 3). Time-updated CD4 showed even more extreme esti-
mates (aHR = 11.79; 95% CI, 4.47–31.07), whereas use of a 3-
month or 6-month lag resulted in slightly attenuated HRs
(Table 3).
In a subgroup analysis among 318 individuals who initiated
ART, individuals who failed to attain at least a 100 cell increase
from nadir in CD4 had a signiﬁcantly higher risk of liver disease
progression (HR = 7.69; 95% CI, 2.60–22.69; see Table 4). In
models using a 3-month or 6-month lag for change in CD4,
the magnitude was attenuated and no longer statistically signiﬁ-
cant (Table 4). These results suggest that more recent drops in
CD4 are more strongly associated with liver events among HIV/
HCV-coinfected IDUs.
Results for the associations between HIV VL measures and
liver disease progression are shown in Table 5. None of the
models investigating HIV RNA as a predictor suggested a sig-
niﬁcant association with liver disease progression. It should be
noted that there was a nontrivial amount of missing data during
follow-up, which may have impacted the time-updated analyses
of HIV VL and liver events in this cohort (Table 5). In general,
adjusted estimates were attenuated relative to unadjusted esti-
mates, suggesting that HIV VL may at most be only a marginal
predictor of liver outcomes when controlling for other factors
(ie, CD4) in this population. Time-updated and 3-month or
6-month lagged analyses of HIV VL did not appreciably change
results (Table 5), nor did analyses of HIV RNA as a log-trans-
formed continuous variable (data not shown).
We observed 20 deaths due to end-stage liver disease in 1170
person-years of follow-up (1.7 liver-related deaths per 100 per-
son-years) in this HIV/HCV-coinfected IDU population. An
additional 34 individuals died for reasons that were not attrib-
uted to liver complications; 32 of these occurred while the pa-
tient remained at risk for primary liver outcomes. Causes given
for nonliver deaths were as follows: non-HIV-related infection/
sepsis (10); HIV-related (8); drug overdose (5); cardiac (3);
accidental/injury (1); renal (1); respiratory (1); unknown (5).
To address the issue of competing risks, we conducted a sensi-
tivity analysis in which ﬁnal models were weighted using inverse
probability weights (IPW) for likelihood of nonliver death based
on individual covariate histories. Results from IPW models ac-
counting for death due to competing causes (data not shown)
were not substantially different than those from the unweighted
models reported here.
DISCUSSION
In this prospective analysis of clinical liver disease progression in
a cohort of HIV/HCV-coinfected IDUs, CD4 was a consistently
Table 2. Unadjusted Relative Hazards of Liver Disease Progres-
sion Events for Baseline Covariates
Variable Unadjusted HR (95% CI)
Age >45 vs ≤45 years 1.57 (0.68, 3.59)
Male vs female 2.33 (0.80, 6.84)
Race/Ethnicity
Black non-Hispanic 1.57 (0.51, 4.82)
Hispanic 1.62 (0.47, 5.54)
White non-Hispanic Referent
History of diabetes 1.52 (0.52, 4.44)
Markers of HBV 0.65 (0.27, 1.59)
HCV Genotype G1 1.58 (0.36, 6.90)
HCV RNA (IU/mL): ≥106 0.72 (0.30, 1.75)
Interferon Treatment 1.78 (0.41, 7.67)
Audit Score ≥8 1.72 (0.48, 6.08)
Concurrent IDU 0.71 (0.27, 1.91)
Over 25 years as IDU 0.90 (0.38, 2.12)
Initiation of ART 1.92 (0.45, 8.33)
Enrollment during 2000–2001 2.37 (0.87, 6.46)
Abbreviations: ART, antiretroviral therapy; AUDIT, alcohol use disorders
identification test; CI, confidence interval; HBV, hepatitis B virus; HCV,
hepatitis C virus; HR, hazard ratio; IDU, injecting drug use.
4 • OFID • Anderson et al
strong inverse predictor of progression across various modeling
strategies. In addition, smaller increases in CD4 count from
nadir among ART initiators were associated with substantially
increased risk of progression. In contrast, there was no evidence
of an effect of HIV VL on clinical progression of liver disease
due to chronic HCV, particularly when CD4 and other covari-
ates were accounted for. Two other groups have reported pro-
tective associations between CD4 and various endpoints related
Table 3. Relative Hazards of Liver Disease Progression Events by CD4 Count (Cells/μL) Status
Variable Person-Years Events Unadjusted HR (95% CI) Adjusteda HR (95% CI)
Nadir CD4 at entry
<100 248 11 2.86 (1.28, 6.38) 3.52 (1.54, 8.06)
≥100 882 13 Referent Referent
Missing 26 0 – –
CD4 Count at Entry
<200 230 13 4.40 (1.97, 9.83) 5.23 (2.30, 11.92)
≥200 892 11 Referent Referent
Missing 33 0 – –
Time-updated CD4
<200 223 16 8.59 (3.53, 20.89) 11.79 (4.47, 31.07)
≥200 844 7 Referent Referent
Missing 89 1 1.56 (0.19, 13.10) 1.46 (0.17, 12.37)
Lagged CD4 (3-month)
<200 218 13 4.63 (2.07, 10.35) 5.88 (2.43, 14.27)
≥200 848 11 Referent Referent
Missing 90 0 – –
Lagged CD4 (6-month)
<200 216 14 5.45 (2.41, 12.28) 7.07 (2.90, 17.26)
≥200 851 10 Referent Referent
Missing 89 0 – –
Abbreviations: CI, confidence interval; HR, hazard ratio.
a Final adjusted models are reduced from fully adjusted models, having removed covariates that did not significantly predict liver disease progression and did not
substantially change the estimate for the association of interest. Models for baseline nadir CD4 and baseline CD4 are adjusted for HCV viral load (≥106, <106) only.
The model for current CD4 is adjusted for HIV viral load (≤75, 76–10 000, >10 000) and calendar year (continuous). The models for lagged CD4 are adjusted for HIV
viral load (≤75, 76–10 000, >10 000) and HCV viral load (≥106, <106).
Table 4. Relative Hazards of Liver Disease Progression Events by Time-Dependent Increase in CD4 Count (Cells/μL) From Nadir Among
ART Initiators (N = 318)
Variable Person-Years Events Unadjusted HR (95% CI) Adjusteda HR (95% CI)
Time-updated change in CD4
≤100 361 16 5.13 (1.88, 14.01) 7.69 (2.60, 22.69)
>100 556 5 Referent Referent
Missing 81 1 1.55 (0.18, 13.73) 3.39 (0.37, 31.33)
Lagged change in CD4 (3-month)
≤100 360 12 1.86 (0.80, 4.32) 1.86 (0.80, 4.32)
>100 557 10 Referent Referent
Missing 81 0 0 (0, ∞) 0 (0, ∞)
Lagged change in CD4 (6-month)
≤100 362 12 1.88 (0.81, 4.36) 1.88 (0.81, 4.36)
>100 557 10 Referent Referent
Missing 80 0 0 (0, ∞) 0 (0, ∞)
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratio.
a Final adjusted models are reduced from fully adjusted models, having removed covariates that did not significantly predict liver disease progression and did not
substantially change the estimate for the association of interest. The model for current change in CD4 is adjusted for HIV viral load (≤75, 76–10 000, >10 000), nadir
CD4 (continuous), and concurrent IDU. Models for lagged change in CD4 do not include any of the covariates under study.
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to chronic hepatitis in IDUs, consistent with our ﬁndings [25,
26]. In our study, baseline CD4, nadir CD4, current CD4, and
lagged CD4 were all strong and signiﬁcant predictors of liver
disease progression and were not strongly inﬂuenced by HIV
VL or other factors in adjusted models. If HIV coinfection ac-
celerates progression to liver outcomes in those with chronic
HCV, then initiation and maintenance of ART would confer
beneﬁt in this context [24–26]. However, CD4 rebound in re-
sponse to ART may be muted among HIV/HCV-coinfected
persons, although results have been inconsistent [27–33]. Fur-
thermore, virologic suppression in response to ART may be de-
creased among current IDUs [40]. Given that CD4 seems to be
an important predictor of liver outcomes among HIV/HCV-co-
infected, those who respond to ART (exhibited by greater in-
creases in CD4 from nadir) should have a slower rate of
progression, which is consistent with our results. It appears
that ART should preferably be administered before immune im-
pairment becomes severe, as evidenced by the strong inverse as-
sociation we observed between nadir CD4 and clinical liver
events.
Human immunodeﬁciency virus has been proposed to di-
rectly infect hepatocytes or indirectly interact with HCV [34].
Our results showed no discernible association between HIV
VL and liver events, especially once CD4 and other factors
were accounted for, which is consistent with some but not all
previous reports [2, 12, 15, 16, 21, 35]. In particular, our ﬁndings
contrast with those presented by Brau et al [35], who reported
that HIV VL signiﬁcantly predicted ﬁbrosis progression rate
while CD4 count did not in a population of coinfected individ-
uals that had undergone liver biopsies.
It should be noted that a high proportion of patients in this
study cohort also had evidence of infection with hepatitis B
(78%), which is perhaps not surprising due to shared parenteral
mode of transmission. This additional viral burden may poten-
tially be an important factor in interpreting and generalizing
these results. However, it should be noted that our analyses
did not show a signiﬁcant association between HBV positivity
and progression of liver disease, and addition of this variable to
adjusted models did not substantially alter estimates for the as-
sociations of interest.
This study has several limitations. First, there were relatively
few observed outcomes, and longer follow-up might have yield-
ed more outcomes. However, estimates from models of CD4
and change in CD4 were consistent and highly statistically sig-
niﬁcant, giving evidence of the strong inﬂuence of CD4 on liver
outcomes and/or proof of concept that signiﬁcant associations
could be detected in this dataset. Second, there was a nontrivial
amount of missing data, particularly among covariates such as
HCV RNA, HCV genotype, and AUDIT score (alcohol intake).
Missing HCV RNA may not be a major concern, because there
Table 5. Relative Hazards of Liver Disease Progression Events by HIV Viral Load (Copies/mL)
Variable Person-Years Events Unadjusted HR (95% CI) Adjusteda HR (95% CI)
HIV RNA at entry
≤75 469 10 Referent Referent
76–10 000 342 5 0.66 (0.22, 1.92) 0.53 (0.18, 1.56)
>10 000 270 8 1.35 (0.53, 3.41) 0.75 (0.28, 2.03)
Missing 75 1 0.64 (0.08, 5.04) 0.57 (0.07, 4.57)
Time-updated HIV RNA
≤75 347 10 Referent Referent
76–10 000 237 2 0.27 (0.06, 1.23) 0.25 (0.05, 1.15)
>10 000 180 6 1.15 (0.42, 3.18) 0.87 (0.31, 2.43)
Missing 391 6 1.20 (0.38, 3.82) 1.28 (0.40, 4.08)
Lagged HIV RNA (3-month)
≤75 365 9 Referent Referent
76–10 000 250 4 0.60 (0.19, 1.97) 0.53 (0.16, 1.75)
>10 000 193 6 1.25 (0.44, 3.51) 0.93 (0.31, 2.76)
Missing 348 5 1.22 (0.36, 4.18) 1.70 (0.47, 6.12)
Lagged HIV RNA (6-month)
≤75 381 9 Referent Referent
76–10 000 263 4 0.62 (0.19, 2.01) 0.54 (0.16, 1.77)
>10 000 203 7 1.42 (0.53, 3.81) 1.06 (0.37, 3.05)
Missing 309 4 1.01 (0.27, 3.80) 1.31 (0.34, 5.12)
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; HR, hazard ratio.
a Final adjusted models are reduced from fully adjusted models, having removed covariates that did not significantly predict liver disease progression and did not
substantially change the estimate for the association of interest. The models for baseline and current HIV viral load are adjusted for baseline CD4 (<200, ≥200) only.
The models for lagged HIV viral load are adjusted for baseline CD4 (<200, ≥200), HCV viral load (≥106, <106), and age (continuous).
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is little evidence to suggest that it predicts liver endpoints, there-
by limiting its potential as a confounder for these analyses. Sim-
ilarly, missing data on HCV genotype may not be overly
troublesome given that genotype 1 appears to be the predomi-
nant virus among IDUs in this study population and elsewhere.
On the other hand, alcohol abuse has been implicated in pro-
gression of liver disease, so missing AUDIT scores may have in-
troduced some bias. A third limitation of this study is that these
results may not be directly generalizable to other populations, in
particular those without a history of injecting drugs. Finally, re-
sidual confounding by unknown or inadequately measured fac-
tors cannot be fully discounted. However, steps were taken
throughout the analysis to assess and minimize confounding
by known risk factors for HCV liver disease progression.
CONCLUSIONS
In summary, baseline and current CD4, nadir CD4, and change
in CD4 from nadir among those on ART were strong predictors
of clinical liver disease progression events in this prospective
analysis of HIV/HCV-coinfected IDUs, whereas other factors
including HIV VL were not. To our knowledge, this is the
ﬁrst time these ﬁndings have been reported in an IDU popula-
tion. Additional prospective studies and experimental studies
are warranted to elucidate the relevant immunologic mecha-
nisms and synergistic pathogenesis of liver disease in HIV/
HCV coinfection. Taken together, these results support prompt
institution of ART for HIV/HCV-coinfected IDUs and careful
attention to those who do not manifest a substantial increase in
CD4 count. However, it remains to be determined whether a
poor CD4 response is causally related to risk of liver disease
progression or whether conditions leading to liver disease pro-
gression by other mechanisms also lead to impaired CD4
response.
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